Quiver Markets Preview: Oil Prices Soar & Intel Stumbles
The U.S. economy's resilience continues to defy expectations, with a robust fourth-quarter GDP growth of 3.3%, eclipsing forecasts of a slowdown. This surge in economic activity, amidst the Federal Reserve's...
Revisiting the classic 60/40 portfolio as challenges loom
Traditionally reliable, the 60/40 portfolio may no longer guarantee solid returns amid concerns about rising interest rates and rising bond yields.
Novartis Shares Leap On Positive Clinical Trial Data
Swiss pharmaceutical giant Novartis leaped 5.11% in the past week following news that its Kisqali breast-cancer treatment cut the probability of relapse.
What Investors Learned When Everything Went Down at Once
The third quarter extended losses for most financial markets.